Published in Am J Epidemiol on April 29, 2008
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med (2011) 2.06
Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.55
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol (2011) 1.23
Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions. Cancer Causes Control (2008) 1.19
The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer (2010) 1.05
Mammographic screening and risk factors for breast cancer. Am J Epidemiol (2009) 0.99
Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev (2010) 0.97
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res (2014) 0.95
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women. Menopause (2012) 0.84
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus (2015) 0.82
The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol (2008) 0.82
Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors. Endocrinology (2010) 0.80
Alcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers Study. Cancer Epidemiol Biomarkers Prev (2012) 0.80
Invited commentary: Postmenopausal unopposed estrogen and breast cancer risk in the Women's Health Initiative--before and beyond. Am J Epidemiol (2008) 0.80
A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause (2014) 0.80
Exogenous estrogen protects mice from the consequences of obesity and alcohol. Menopause (2012) 0.78
Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology (2008) 0.78
Embedding clinical interventions into observational studies. Contemp Clin Trials (2015) 0.77
Breast cancer risk factors. Prz Menopauzalny (2015) 0.76
Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat (2011) 0.76
Re: "Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study". Am J Epidemiol (2008) 0.75
Should hormone replacement therapy be used in postmenopausal women for voiding dysfunction? Can Urol Assoc J (2009) 0.75
Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. Menopause (2016) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol (2000) 3.24
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology (1998) 2.18
Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat (2005) 1.08
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med (2004) 9.62
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev (2004) 7.57
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35